Rythmol SR Warning Letter Cites Lack Of "Any" Risk Information
This article was originally published in The Pink Sheet Daily
Executive Summary
Promotional pieces aimed at encouraging pharmacy stocking expand the antiarrhythmic's indication and obscure its risks, FDA's ad division says.